Resources from the same session
LBA43 - 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma
Presenter: James Larkin
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA44 - Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Presenter: Caroline Robert
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA45 - Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial
Presenter: Dirk Schadendorf
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA43, LBA44 and LBA45
Presenter: Jessica Hassel
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Slides
Webcast
1077MO - Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K
Presenter: Georgina Long
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1078MO - Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716
Presenter: Jason Luke
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1079MO - Survival before and after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
Presenter: Hildur Helgadottir
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA46 - Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
Presenter: Caroline Robert
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1080MO - Sitravatinib plus tislelizumab for metastatic uveal melanoma with liver metastasis: The open-label, multicenter, phase II GEM-2101 trial
Presenter: Luis del Carpio Huerta
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1081MO - Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma
Presenter: Paolo Ascierto
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast